» Articles » PMID: 15390107

Expression of Indoleamine 2,3-dioxygenase and Production of Quinolinic Acid by Human Microglia, Astrocytes, and Neurons

Overview
Journal Glia
Specialty Neurology
Date 2004 Sep 25
PMID 15390107
Citations 228
Authors
Affiliations
Soon will be listed here.
Abstract

There is good evidence that the kynurenine pathway (KP) and one of its end products, quinolinic acid (QUIN) play a role in the pathogenesis of several major neurological diseases. While QUIN has been shown to be produced in neurotoxic concentrations by macrophages and microglia, the capacity of astrocytes and neurons to produce QUIN is controversial. Using interferon gamma (IFN-gamma)-stimulated primary cultures of human mixed brain cells, we assayed expression of the KP regulatory enzyme indoleamine 2,3-dioxygenase (IDO) and QUIN production by immunocytochemistry. Using IFN-gamma-stimulated purified cultures of neurons, astrocytes, microglia and macrophages, we studied IDO expression by RT-PCR and production of QUIN using mass spectrometry. We found that astrocytes, neurons, and microglia expressed IDO but only microglia were able to produce detectable amounts of QUIN. However, astrocytes and neurons had the ability to catabolize QUIN. This study also provides the first evidence of IDO expression and lack of production of QUIN in culture of primary human neurons.

Citing Articles

Galantamine-Memantine Combination in the Treatment of Parkinson's Disease Dementia.

Frost E, Shi S, Byroju V, Rissardo J, Donlon J, Vigilante N Brain Sci. 2025; 14(12.

PMID: 39766362 PMC: 11674513. DOI: 10.3390/brainsci14121163.


Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities.

Pocivavsek A, Schwarcz R, Erhardt S Pharmacol Rev. 2024; 76(6):978-1008.

PMID: 39304346 PMC: 11549936. DOI: 10.1124/pharmrev.124.000239.


Neurodevelopmental and Neuropsychiatric Disorders.

Traetta M, Chaves Filho A, Akinluyi E, Tremblay M Adv Neurobiol. 2024; 37:457-495.

PMID: 39207708 DOI: 10.1007/978-3-031-55529-9_26.


Kynurenines and Inflammation: A Remarkable Axis for Multiple Sclerosis Treatment.

Carrillo-Mora P, Landa-Solis C, Valle-Garcia D, Luna-Angulo A, Aviles-Arnaut H, Robles-Banuelos B Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204088 PMC: 11356993. DOI: 10.3390/ph17080983.


The Biology and Biochemistry of Kynurenic Acid, a Potential Nutraceutical with Multiple Biological Effects.

Alves L, Moore J, Kell D Int J Mol Sci. 2024; 25(16).

PMID: 39201768 PMC: 11354673. DOI: 10.3390/ijms25169082.